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1. Introduction 
Elevated sympathetic activation, as assessed using a variety of indices, has been observed in 
lean hypertensive and diabetic patients, and obese individuals [Huggett et al. 2006; Masuo et 
al. 2000]. Similarly, many epidemiological studies have shown that hypertensive patients, 
even those without increased adiposity, display a higher prevalence of insulin resistance, 
thereby indicating the possible association between sympathetic activation and insulin 
resistance in the pathogenesis of hypertension [Esler et al. 2006; Masuo et al. 2002; de Silva et 
al. 2009]. Overweight and obesity is a growing problem across the globe and has reached 
“epidemic” proportions. The prevalence of diabetes, especially type 2 diabetes, and 
hypertension are significantly increased with the prevalence of obesity. Obesity, itself, and 
type 2 diabetes and hypertension associated with obesity are known to be more closely 
linked with insulin resistance and elevated sympathetic nervous activity. It has been well 
documented that obesity, hypertension, and diabetes are risk factors for subsequent 
cardiovascular and renal complications. Many patients are both diabetic and hypertensive 
while they are obese, but not all diabetic patients have hypertension, indicating that insulin 
resistance is not the only mechanism for blood pressure elevation in diabetic-hypertensive 
patients. Several investigators have reported that sympathetic nervous activation plays an 
important role in cardiovascular complications in patients with hypertension, diabetes, and 
obesity. 
Sympathetic nervous activation accompanying insulin resistance is closely linked with left 
ventricular hypertrophy in otherwise healthy subjects [Masuo, et al. 2008]. In addition, 
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sympathetic activation may predict the development of renal injury in healthy normotensive 
subjects [Masuo, et al. 2010]. Weight loss associated suppression of sympathetic nervous 
activity is associated with improvement of insulin sensitivity and resultant improvement in 
renal function in obese patients [Masuo, et al. 2011b; Straznicky, et al. 2009b & 2011]. 
Furthermore, weight loss improved the prevalence of left ventricular hypertrophy [Masuo, 
et al. 2008], which is one of the predictors for future cardiac complications, renal 
complications (injury) [Masuo, et al. 2007] and hyperuricacidemia [Straznicky, et al. 
2011].These findings suggest that elevated sympathetic nerve activity associated with 
insulin resistance may contribute to the onset and maintenance of cardiovascular and renal 
complications in diabetes, and hypertension in obesity.  
Furthermore, genetic polymorphisms of the β2- and β3-adrenoceptor gene have been 
associated with obesity [Masuo, et al. 2005 & 2011a; Kawaguchi, et al. 2006], hypertension 
[Masuo, et al. 2005b & 2010b; Kawaguchi, et al. 2006], type-2 diabetes and insulin resistance 
[Masuo, et al. 2005 & 2010} in epidemiological studies and may also be implicit in the close 
relationship between insulin resistance and sympathetic nerve activation. Recently, Masuo 
et al. reported that β2-adrenoceptor polymorphisms (Arg16Gly) accompanying high plasma 
norepinephrine levels may contribute to the prevalence of left ventricular hypertrophy and 
renal dysfunction [Masuo, et al. 2010a, b & 2011b]. These investigations suggest that β2-
adrenoceptor polymorphisms are related to sympathetic activation and insulin resistance 
and may contribute to cardiovascular- and renal complications in obesity and obesity-
related hypertension or type 2 diabetes. 
This chapter will provide a synthesis of the current findings on the mechanisms of the onset 
and maintenance of cardiovascular and renal complications in obesity, hypertension and 
type 2 diabetes, with a particular focus on sympathetic nervous activity and insulin 
resistance. A better understanding of the relationships between sympathetic nervous 
activity and insulin resistance in these important clinical conditions might help with the 
clinical treatment of diabetes and hypertension in obesity and prevent further 
cardiovascular and renal complications in this at risk group.  
2. Prevalence of type 2 diabetes and hypertension in obesity 
The clustering of cardiovascular risk factors associated with obesity, in particular abdominal 
obesity, is well established [Athyrus, et al. 2011]. The prevalence of obesity and overweight 
increased in the United States between 1978 and 1991 [Mokdad, et al. 2001], and recent 
reports have suggested continuing increases [Ogden, et al. 2004]. The National Health and 
Nutrition Examination Survey (NHANES) I (1971-1974), NHANES II (1976-1980), and 
NAHNES III (1988-1994) were conducted by the National Center for Health Statistics, 
Centers for Disease Control and Prevention (CDC). These data from the continuous 
NHANES studies have  showed that the prevalence of obesity and overweight people 
increased significantly in the United States between 1960 and 2003 [Preis, et al. 2009; Ogden, 
et al. 2004; Flegal, et al. 2012]. Evidence from several studies indicates that obesity and 
weight gain are associated with an increased risk of hypertension [Masuo, et al. 2000 & 
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2005a, b, c] and diabetes [Resnick, et al. 2000; Ford, et al. 1997], and that intentional weight 
loss reduces the risk that overweight individuals will develop hypertension [Masuo, et al. 
2001b; Straznicky, et al. 2009b] or diabetes [Will, et al. 2002].  
Recent large cohort studies have showed an increasing prevalence of obesity in children 
and, importantly, obesity in children is strongly associated with several major health risk 
factors, including type 2 diabetes mellitus and hypertension [Hedley, et al. 2004]. 
Focusing on the close associations between obesity, hypertension and diabetes, the 
NHANES and the Behavioural Risk Factor Surveillance System (BRFSS) investigations 
[Mokdad, et al. 2003] showed very close relationships between the prevalence of obesity, 
hypertension, and diabetes. Further, the Framingham Heart Study [Preis, et al. 2009] 
showed that diabetic subjects had a 2-fold higher mortality risk consisting of cardiovascular 
and non-cardiovascular mortality.  
3. Sympathetic nervous activity in obesity, hypertension and diabetes 
The sympathetic nervous system represents a major pathophysiological hallmark of both 
hypertension and renal failure, and is an important target of the therapeutic intervention 
[Grassi, et al. 2012; Schlaich, et al. 2009]. The sympathetic nervous system participates in 
regulating the energy balance through thermogenesis. Reduced energy expenditure and 
resting metabolic rate are predictive of weight gain (obesity). It is also widely recognized that 
insulin resistance or hyperinsulinemia relates to obesity [Minicardi, et al. 1996; Farrannini, et al. 
1995; Ward, et al. 1996]. Many epidemiological and clinical studies have shown a close 
relationship between sympathetic nervous system activity and insulin levels in obesity 
[Masuo. et al. 2002]. Several studies of longitudinal design have examined the effect of body 
weight changes (weight loss or weight gain) on sympathetic nervous system activity and 
insulin sensitivity (fasting plasma insulin levels and the (homeostasis model assessment of 
insulin resistance,   HOMA-IR). Elevations of sympathetic nervous system activity and insulin 
levels during weight gain [Masuo, et al. 2000; Gentale, et al. 2007; Barms, et al. 2003], and 
reductions of sympathetic activity and insulin levels during weight loss [Anderson, et al. 1991; 
Straznicky, et al. 2009], are typically observed. While these longitudinal studies have clearly 
shown that heightened sympathetic nerve activity and insulin resistance are closely linked to 
obesity (weight gain), the onset of obesity and the maintenance of obesity, it remains to be 
elucidated, whether sympathetic hyperactivity or insulin resistance is the prime mover.  
The response of the sympathetic nervous system to change in plasma insulin levels after oral 
glucose loading (oral glucose tolerance test) are different between subjects with and without 
insulin resistance [Masuo, et al. 2005], between nonobese and obese subjects [Straznicky, et al. 
2009a], and between subjects with and without the metabolic syndrome [Straznicky. 2009b]. 
Recently, changes in the sympathetic nerve firing pattern were observed with sympatho-
inhibition during weight loss [Lambert, et al. 2011].  In addition, different regulation by insulin 
of regional (i.e. hind limb, kidney and brown adipose tissue) sympathetic outflow to 
peripheral tissue was observed in agouti obese mice compared to lean control mice [Morgani, 
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et al. 2010]. These observations provide the evidence of a strong linkage between the activity of 
the sympathetic nervous system and insulin levels. Huggett et al. [Huggett, et al. 2003] 
examined muscle sympathetic nerve activity (MSNA) in four groups of subjects, patients with 
essential hypertension and type 2 diabetes, patients with type 2 diabetes alone, patients with 
essential hypertension alone, and healthy normotensive controls. They found higher MSNA in 
the hypertensive-type 2 diabetic patients as compared with hypertensive alone patients or type 
2 diabetic alone patients, and higher MSNA in hypertensive alone patients or type 2 diabetic 
alone patients as compared with healthy normotensive controls. Fasting insulin levels were 
greater in hypertensive-type 2 diabetic patients and type 2 diabetic patients compared to 
hypertensive patients or healthy normotensive subjects. These findings, although obtained in 
patients still under medication, provided evidence that type 2 diabetic patients had elevated 
sympathetic nerve activity regardless of the prevailing blood pressure levels, and that the 
combination of hypertension and type 2 diabetes resulted in an augmentation in sympathetic 
nerve activity and levels of plasma insulin.  
Several investigations on the contributions of β2- and β3-adrenoceptor polymorphisms to 
type 2 diabetes also support a strong relationship between sympathetic nerve hyperactivity 
and insulin resistance in type 2 diabetes [Masuo, et al. 2004 & 2005a, b; Ikarashi, et al. 2004]. 
Figure 1 summarizes the relationships between sympathetic nerve activity and insulin 
resistance in obesity and type 2 diabetes mellitus (Figure 1). 
 
Obesity causes both insulin resistance/hyperinsulinemia and sympathetic nervous activation, and both link closely 
each other. Many investigations have shown that insulin resistance, sympathetic nervous activation, and adrenoceptor 
polymorphisms play important roles in the onset and maintenance of obesity, type 2 diabetes and hypertension.  
T2DM, type 2 diabetes, RAA, renin-angiotensin-aldosterone system; ADRB polymorphisms, adrenoceptor 
polymorphisms; SNS, sympathetic nervous system.  
Figure 1. Potential pathophysiological mechanisms in obesity, hypertension and type2diabetes (T2DM) 
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4. Insulin resistance in obesity, hypertension and type 2 diabetes 
Insulin resistance [Ferrannini, et al. 1998] is one of the criteria underpinning the 
development of the metabolic syndrome. The clinical evaluation of insulin resistance is 
growing interest because it is a strong predictor and plays an important role in the 
development of the metabolic syndrome, type 2 diabetes mellitus and hypertension. 
Table 1 shows the criteria for metabolic syndrome characterisation, as can be seen 
insulin resistance is prominent [Alberti, et al. 1998; Grundy, et al. 2004] (Table 1). 
Measuring insulin sensitivity is important to define insulin resistance. Table 2 
summarizes the methods usually used in clinical and epidemiological studies (Table 2). 
The hyperinsulinemic-euglycemic glucose clamp method is the gold standard and may 
be suitable for research investigations in specialized laboratories, but the homeostasis 
model assessment of insulin resistance (HOMA-IR) or fasting plasma insulin 
concentrations is more practical for epidemiological studies comprising a large number 
of subjects.   
4.1. Hyperinsulinemia as a marker of insulin resistance 
Insulin is an exceptional hormone in that its action is regulated not only by changes in 
concentration but also by changes in the sensitivity of target tissues. Inadequate insulin 
action can be the consequence of: (i) insufficient insulin concentration at the site of action, (ii) 
decreased tissue (effectors) responses to insulin, or (iii) a combination of low concentration 
and a decreased response. Regulation of circulating insulin levels is mainly (but not 
exclusively) achieved by changes in secretory rates. Nevertheless, the major determinant of 
insulin secretion, and therefore of plasma insulin concentration, is glucose. Any change in 
glucose concentration from the narrow normal range results in an insulin response 
appropriate to restore homeostasis. Thus, changes in insulin sensitivity occur in various 
physiological states and pathological conditions. 
For any amount of insulin secreted by the pancreas, the biological response of a given 
effector is dependent on its insulin sensitivity. The term insulin resistance customarily refers 
to glucose metabolism. Any decrease in insulin sensitivity (insulin resistance) is 
immediately translated into minute increases in blood glucose concentrations that will in 
turn act on the β-cell to produce a compensatory stimulus of insulin secretion, leading to a 
degree of hyperinsulinemia that is approximately proportional to the degree of effector 
resistance. Therefore, hyperinsulinemia may be responsible for insulin resistance. In steady-
state conditions, this compensatory hyperinsulinemia prevents a more exaggerated 
hyperglycaemia. The inability of β-cells to enhance insulin secretion means that blood 
glucose will keep increasing until the level of hyperglycaemia produces an adequate β-cell 
stimulus to attain the required insulin response. When the β-cell is unable to compensate for 
the prevalent insulin resistant state by further augmenting insulin secretion, hyperglycaemia 
continues to increase, producing impaired fasting glucose, impaired glucose tolerance and 














BMI, body mass index; EGIR, European Group of the study of Insulin Resistance; NCEP ATPIII, 3rd Recommendations of the Adult Treatment Panel of the National 
Cholesterol Education Program; HDL-cholesterol, high-density lipoprotein cholesterol. Values in NECP definition and American Heart Association/Updated NCEP are 
approximations of values in mg/dL. 
Table 1. Criteria for Metabolic Syndrome including Insulin Resistance (50) 
 















IR, insulin resistance; AUS, the area under the curve; ISI, insulin sensitivity index  
Table 2. Methods for Measuring Insulin Sensitivity 
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4.2. Relationships between sympathetic nervous activity and insulin resistance 
in obesity, hypertension, and type 2 diabetes 
It is widely recognized that insulin resistance or hyperinsulinemia relates to obesity 
[Ferrannini, et al. 1991 & 1995; Ward, et al. 1996], but the precise relationships linking those 
factors remain controversial. Many epidemiological and clinical studies have shown a close 
relationship between sympathetic nervous system activity and insulin levels in obesity 
[Anderson, et al. 1991; Ward, et al. 1996; Masuo, et al. 2002]. Several studies of longitudinal 
design have examined the effect of body weight changes (weight loss or weight gain) on 
sympathetic nervous system activity and insulin sensitivity (fasting plasma insulin levels 
and HOMA-IR). Elevations of sympathetic nervous system activity and insulin levels during 
weight gain [Masuo, et al. 2000; Bernes, et al. 2003; Gentle, et al. 2007} and reductions of 
sympathetic nerve activity and insulin levels during weight loss [Masuo, et al. 2001; 
Andersson, et al. 1991; Straznicky, et al, 2010] have been observed. These longitudinal studies 
have shown that heightened sympathetic nerve activity and insulin resistance are closely 
linked to obesity (weight gain), the onset of obesity and the maintenance of obesity.  In 
addition, a calorie restricted diet and exercise may have different mechanism on weight 
loss-induced blood pressure reduction.  Figure 2 shows changes in neurohormonal 
parameters over a 24-week period weight loss regimens  with a mild calorie restricted diet 
alone, mild exercise alone, or a combination with a mild calorie restricted diet and mild 
exercise. This study showed that a calorie restricted diet contributed strongly to 
normalization/suppression of sympathetic activation, and exercise related to insulin 
resistance.  In addition, calorie restricted diet and exercise may have different mechanisms 
on weight loss-induced blood pressure reduction [Masuo, et al. 2012a].  
Reduced energy expenditure and resting metabolic rate are predictive of weight gain and 
obesity development. The sympathetic nervous system participates in regulating energy 
balance through thermogenesis (Figure 1). Landsberg and other investigators hypothesized 
that energy intake stimulates hyperinsulinemia and sympathetic nerve activity resulting in 
blood pressure elevations in a cycle in order to inhibit thermogenesis. Insulin-mediated 
sympathetic nerve stimulation in obese subjects is therefore considered part of a 
compensatory mechanism aimed at restoring the energy balance by increasing the metabolic 
rate [Landsberg. 2001]. Hyperinsulinemia and insulin resistance in obese subjects are all part 
of a response to limit further weight gain via stimulating sympathetic nerve activity and 
thermogenesis [Landsberg, 2001].  
On the other hand, Julius and Masuo generated a hypothesis based on data from their 
longitudinal studies that increased sympathetic nerve activity in skeletal muscle causes 
neurogenic vasoconstriction, thereby reducing blood flow to muscle and consequently 
inducing a state of insulin resistance by lowering glucose delivery and uptake in 
hypertension and obesity. Both blood pressure elevations and weight gain may reflect a 
primary increase in sympathetic nervous tone. Masuo et al. [Masuo, et al. 1997, 2000, and 
2003] demonstrated that high plasma norepinephrine could predict future blood pressure 
elevations accompanying deterioration in insulin resistance. This was observed in HOMA-
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IR (homeostasis model assessments of insulin resistance) in nonobese, normotensive 
subjects using longitudinal studies. Rocchini et al. [Rocchini, et al. 1990] reported that 
clonidine prevented insulin resistance development in obese dogs over a 6-week period, 
suggesting that sympathetic nervous activity might play a major role in the development of 
insulin resistance accompanying blood pressure elevation. The longitudinal studies 
[Straznicky, et al. 2005, 2009b & 2012. Masuo, et al. 2000, 2001b, 2003, 2005a, 2012] might 
provide strong evidence for a close linkage of high sympathetic nervous activity 
accompanying insulin resistance with the onset of hypertension. Heightened sympathetic 
nerve activity might play a major role in blood pressure elevations, and insulin resistance 
might play an ancillary mechanism for blood pressure elevation and genesis of 
hypertension. In hypertensive patients who already have heightened sympathetic nerve 
activity and insulin resistance, both heightened sympathetic nerve activity and insulin 
resistance are related to further blood pressure elevations.  
 
During weight loss with a mild calorie restricted diet, normalization of sympathetic activation measured by plasma 
norepinephrine was observed following significant weight loss and normalization of insulin resistance (HOMA-IR). 
On the other hand, in exercise alone group, normalization of insulin resistance was observed, and then weight loss and 
suppression of sympathetic activation. A low caloric diet and exercise may exert different effects on weight loss. NE, 
plasma norepinephrine levels; Fat, total body fat-mass; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
HOMA, homeostasis model of assessment of insulin resistance. [Masuo, et al. 2012] 
Figure 2. When significant changes were observed comparisons between a calorie restricted diet vs. 
mild exercise alone vs. combination with diet + exercise over 24 weeks 
Very recently, Masuo et al. [Masuo, et al. 2012} showed the differences in mechanisms of 
weight loss-induced blood pressure reductions with neurohormonal parameters changes 
over 24 weeks with loss regimens (Figure 2). A calorie restricted diet caused 
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suppression/normalization of sympathetic activation measured with plasma norepinephrine 
levels followed by improvements of insulin resistance, whereas exercise improved insulin 
resistance followed by normalization of norepinephrine levels. BMI and blood pressure 
decreased after significant reductions in both plasma norepinephrine and HOMA-IR (Figure 
2).  Their investigations may help to explain why discordant results have been observed.  
However, at least their hypotheses showed a strong linkage between sympathetic activation, 
insulin resistance, obesity and hypertension.  
Valentine et al. [Valentine, et al. 2004] reported attenuation of hemodynamic and energy 
expenditure responses to isoproterenol infusion in hypertensive patients. Their findings that 
a generalized decrease of β-adrenergic responsiveness in hypertension supports the 
hypothesis that heightened sympathetic nerve activity through down-regulation of β-
adrenoceptor-mediated thermogenesis, may facilitate the development of obesity in 
hypertension. Their results suggested that sympathetic nerve activity-induced hypertension 
may subsequently lead to the development of obesity.  
Hoffmann et al. [Hoffmann, et al. 1999] investigated the effects of the acute induction of 
hyperglycemia on sympathetic nervous activity and vascular function in eight young 
normal control subjects. Muscle sympathetic nerve activity (MSNA) and forearm vascular 
resistance were measured before and during systemic infusion of 20% dextrose with low 
dose insulin with 60 min of hyperglycemia. Acute hyperglycemia caused sympathetic 
activation and peripheral vasodilation. Moreover, both acute and chronic hyperglycemia 
and hyperinsulinemia may enhance adrenergic vasoconstriction and decrease vasodilation 
in animal models (pithed rats) [Takatori, et al. 2006; Zamai, et al. 2008]. Insulin causes 
forearm vasoconstriction in obese, insulin resistant hypertensive humans [Gudbjornsdotti, et 
al. 1998]. On the other hand, van Veen et al. [van Veen, et al. 1999] found that hyperglycemia 
induced vasodilation in the forearm, but this vasodilation was not modified by 
hyperinsulinemia.  
4.3. Sympathetic nervous activity and leptin in obesity and the metabolic 
syndrome 
Interactions between the sympathetic nervous system and leptin are widely acknowledged 
with each being able to influence the other. Indeed, the leptin system mediates some of its 
action through the sympathetic nervous system [Haynes, et al. 1997; Kuo, et al. 2003]. 
Trayhurn et al. [Trayhurn, et al. 1995; Hardie, et al. 1996] investigated the effect of acute 
sympathetic nerve activation caused by exposure to cold on the expression of the leptin gene 
in white adipose tissue of lean mice, but not in obese mice. In addition, Masuo et al. reported 
the blunted linkage between the sympathetic nervous system and leptin in obese subjects 
[Masuo, et al. 2006; Kawaguchi, et al. 2006]. These studies, together with others, indicate that 
both insulin resistance and leptin may be regulated by the sympathetic nervous system. 
Masuo et al. [Masuo, et al. 2008] showed during oral glucose loading that plasma insulin and 
plasma norepinephrine increased in both insulin-sensitive and insulin-resistant subjects, but 
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plasma leptin levels decreased in insulin-sensitive nonobese subjects and increased in 
insulin- resistant nonobese subjects. Straznicky et al. [Straznicky, et al. 2005] also reported 
the blunted responses of whole-body norepinephrine spillover, insulin, and plasma leptin 
during oral glucose loading in obese subjects with insulin resistance as compared to insulin 
sensitive subjects. In subjects with the metabolic syndrome, weight loss with a low caloric 
diet diminished the whole-body and regional sympathetic nerve activity, as indicated by 
determinants of the whole-body norepinephrine spillover to plasma and muscle 
sympathetic nerve activity. Of interest, the decrease in norepinephrine spillover to plasma 
after weight loss was positively and independently associated with the decrease in plasma 
leptin, but not with insulin sensitivity in overweight insulin resistant subjects, while in 
overweight subjects without insulin resistance, the decrease in plasma norepinephrine after 
weight loss correlated with the improvement of insulin sensitivity. 
4.4. Sympathetic nervous activity and insulin resistance in the metabolic 
syndrome 
The metabolic syndrome is a cluster of abnormalities with basic characteristics being insulin 
resistance and visceral obesity. The criteria/definitions of metabolic syndrome are shown in 
Table 1. Importantly, obesity and the metabolic syndrome are associated with significant co-
morbidities, such as type 2 diabetes, cardiovascular disease, stroke, and certain types of cancers.  
Huggett et al. [Huggett, et al. 2003 % 2004] demonstrated in a series of studies using 
microneurography (muscle sympathetic nerve activity, MSNA) that type 2 diabetic patients 
had elevated sympathetic nerve activity regardless of the prevailing level of blood pressure, 
and that the combination of hypertension and type 2 diabetes resulted in an augmentation 
in sympathetic nerve activity and levels of plasma insulin. They also compared MSNA and 
insulin levels in 23 non-diabetic offspring of type 2 diabetic patients and 23 normal control 
individuals [Huggett, et al. 2006]. In non-diabetic offspring of type 2 diabetic patients, the 
fasting plasma levels of insulin and MSNA were greater (p<0.009 and p<0.003) than control 
subjects. Sympathetic nerve activity was significantly correlated to insulin levels (p<0.0002) 
and resistance (p<0.0001) in offspring of type 2 diabetic patients, but not in control subjects. 
Sympathetic activation occurred in not only subjects with the metabolic syndrome, diabetic 
patients, but also in normotensive non-diabetic offspring of patients with type 2 diabetes 
with the degree of activation being in proportion to their plasma insulin levels. This series of 
studies indicates the presence of a mechanistic link between hyperinsulinemia and 
sympathetic activation, both of which could play a role in the subsequent development of 
cardiovascular risk factors. 
5. Cardiovascular and  renal complications in obesity, obesity-related 
hypertension and diabetes 
It has been documented that patients with obesity, hypertension and type 2 diabetes 
frequently have cardiovascular and renal complications. Obesity was closely associated with 
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an increase in blood pressure, left ventricular mass, and with early signs of disturbed left 
ventricular diastolic function [Wikstrand, et al. 1993], and changes in left ventricular 
morphology and diastolic function [Alpert, et al. 2012].  It is well known that sudden cardiac 
death is the most common cause of death in dialysis patients and is usually preceded by 
sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation [Alpert, et al. 
2011]. Left ventricular (LV) mass and loading conditions that may affect LV mass are 
important determinants of corrected QT intervals (QTc) in normotensive severely obese 
subjects [Mukergi, et al. 2011]. The RICARHD study (Cardiovascular risk in patients with 
arterial hypertension and type 2 diabetes study), was a multicenter and cross-sectional 
study, conducted in Spain and included 2,339 patients who were 55 years or more with 
hypertension and type 2 diabetes of greater than 6 months duration. Left ventricular 
hypertrophy (LVH) or renal damage (GFR<60 ml/min/1.73 m2 and/or albumin/creatinine 
ratio ≥0 mg/g or an urinary albumin excretion ≥30 mg/24 hours) were compared between 
these hypertensive and type 2 diabetes patients and healthy controls. The combined 
presence of both hypertension and type 2 diabetes were associated with an increased 
prevalence of established cardiovascular diseases. Similarly, the presence of both cardiac 
and renal damage was associated to the higher prevalence of cardiovascular diseases [Cea-
Calvo, et al. 2006].  
The Lifestyle Interventions and Independence for Elders (LIFE) study in 8,029 patients with 
stage II-III hypertension with LVH on ECG showed high prevalence of co-existence of LVH 
and albuminuria [Wachtell, et al. 2002]. In patients with moderately severe hypertension, 
LVH on two consecutive ECGs is associated with increased prevalence of micro- and macro-
albuminuria compared to patients without persistent LVH on ECG. High albumin excretion 
was related to LVH independent of age, blood pressure, diabetes, race, serum creatinine or 
smoking, suggesting parallel cardiac damage and albuminuria. 
5.1. Hyperglycemia and insulin resistance as risk factors of cardiovascular 
complications in type 2 diabetes 
Hyperglycemia and hyperinsulinemia or insulin resistance that is a characteristic of type 2 
diabetes and obesity play major roles in the cardiovascular complications of type 2 diabetes 
mellitus and obesity. Hyperglycemia is the major risk factor for microvascular complications 
(retinopathy, neuropathy, and nephropathy) in type 2 diabetes, however 70% or 80% of 
patients with type 2 diabetes die of macrovascular disease. Atherogenic dyslipidemia 
(elevated triglyceride levels, low HDL-cholesterol levels, high LDL-cholesterol levels) is the 
major cause of atherosclerosis in patients with type 2 diabetes [Reasner, et al. 2008]. 
Several investigators have demonstrated that insulin resistance could predict future type 2 
diabetes even in nonobese individuals [Morrison, et al. 2008], and even in children [Koska, et 
al. 2007; Morrison, et al. 2008] Insulin resistance accompanying sympathetic nerve activation 
may also predict future hypertension development [Masuo, et al. 1997, 1998, 2003, & 2005]. 
Insulin resistance coexisting with inflammation may predict cardiac disease but, 
interestingly, not stroke in the Japanese diabetic population [Matsumoto, et al. 2006]. 
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Hyperglycemia (i.e. elevated plasma glucose levels) can also predict hospitalization for 
congestive heart failure in patients at high cardiovascular risk [Held, et al. 2007]. 
Hyperglycemia and insulin resistance are risk factors of cardiovascular complications. 
5.2. Sympathetic nervous activity as a risk factor for cardiovascular 
complications and renal complications 
Heightened sympathetic nerve activity plays an important role in cardiovascular 
complications and cardiac risk in humans [Esler, et al. 2000]. There is consistent evidence 
that high plasma norepinephrine level, as an index of heightened sympathetic nerve 
activity, predicts mortality in cardiovascular diseases such as chronic congestive heart 
failure [Cohn et al. 1984; Brum, et al. 2006], left ventricular dysfunction [Grassi, et al. 2009], 
remodelling [Abel, et al. 2010], structural changes in obesity {Benedict, 1996}, and end-stage 
renal disease (ESRD) [Masuo, et al. 2007; Grassi, et al. 2012; Benedict, et al. 1996; Ksiazck, et al.  
2008]. Renal injury also predicts the development of cardiovascular disease [Masuo, et al. 
2007; Joles, et al. 2009].  
Hogarth et al. [Hogarth, et al. 2001] reported that acute myocardial infarction (AMI) in 
hypertensive patients resulted in greater sympathetic nervous activity, persisting for at least 
6 months longer than in normotensive subjects, indicating that AMI further augmented the 
sympathetic nerve hyperactivity of hypertension. Sympathetic nerve hyperactivity could be 
one mechanism involved in the reported worse prognosis in AMI in hypertensive patients 
[Hogarth, et al. 2001]. The sympathetic activation that follows AMI has been associated with 
increased morbidity and mortality in both anterior-AMI and inferior-AMI, with a similar 
magnitude of sympathetic nerve hyperactivity [Graham, et al. 2004]. Patients with 
congenital long-QT syndrome are susceptible to life-threatening arrhythmias, and the 
sympathetic nervous system may have an important triggering role for cardiovascular 
events this condition [Shamsuzzaman, et al. 2001]. 
Changes in heart rates during exercise and recovery from exercise are mediated by the 
balance between sympathetic and vagal activity, and changes in heart rates were evaluated 
in a total of 5,713 asymptomatic working men cohort (between the ages of 42 and 53 years) 
in whom there was no evidence of the presence or history of cardiac disease over the 
preceding 23 years. Baseline heart rates, changes in heart rates during exercise and recovery 
were strongly related to an increased risk of sudden death from myocardial infarction 
[Jeuven, et al. 2005].   
Zoccali et al. [Zoccali, et al. 2002 & 2004] examined the relationships between sympathetic 
nerve activity (plasma norepinephrine levels) and mortality and cardiovascular events in 
228 patients undergoing chronic hemodialysis originally without heart failure. They 
found 45% of dialysis subjects had significantly high plasma norepinephrine levels 
located in the upper limit of the normal range. One-hundred and twenty four (124) fatal 
and nonfatal cardiovascular events occurred in 85 patients during the follow-up period 
(34±15 months). Plasma norepinephrine levels proved to be an independent predictor of 
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fatal and nonfatal cardiovascular events in a multivariate Cox regression model.  
Recently, Joles et al. reported that sympathetic nerve stimulation contributes to the 
progression of renal disease [Joles, et al. 2004]. Masuo et al. reported that plasma 
norepinephrine levels predicted future renal injury in normotensive healthy subjects over 
a 5-year follow up study in a Japanese cohort [Masuo, et al. 2007]. They also found that 
plasma norepinephrine levels were associated with concentric left ventricular 
hypertrophy in these patients [Zoccali, et al. 2002 a & 2002b]. 
Petersson et al. [Petersson, et al. 2002] showed that increased cardiac sympathetic nervous 
activity in renovascular hypertension might lead to high cardiovascular mortality and 
morbidity. Prolonged sympathetic nerve stimulation and elevated circulating 
norepinephrine levels can induce changes in intra-renal blood vessels. Catecholamines 
can induce proliferation of smooth muscle cells and adventitial fibroblasts in vascular 
wall. 
The association between hypertension, obesity and chronic kidney disease (CKD) is well 
recognized [White, et al. 2005; Hall, et al. 2001; Zoccali, et al. 2002].  Obesity and hypertension 
also leads to an increase in the incidence of metabolic diseases such a type 2 diabetes 
mellitus, which is frequently associated with renal injury (proteinuria/microalbuminuria). In 
the majority of cases, ESRD occurs as a result of complication of diabetes or hypertension 
[WHO. 1995]. Obesity, hypertension and type 2 diabetes are characterized as stimulated 
sympathetic nervous activity and insulin resistance states, indicating renal injury and ESRD 
are strongly related to sympathetic nervous activity and insulin resistance. Masuo et al. 
reported that significant weight loss resulted in significant amelioration on renal function 
following suppression on sympathetic activation and hyperinsulinemia (insulin resistance) 
[Masuo, et al. 2012].  The findings suggest that strong linkage between sympathetic nervous 
activity, insulin resistance and renal function.  
Joles et al. reported that sympathetic nerve stimulation contributes to the progression of 
renal disease [Joles, et al. 2004]. The 40-minute infusion of NE into the renal artery of dogs 
produced a reversible ischemic model of acute renal failure [Bulger, et al. 1982]. Another 
study demonstrated renal protection by β-adrenergic receptor blockade in a 
nephrectomized rat experiment without any BP changes [Amam, et al. 2001]. There is 
consistent evidence that high plasma norepinephrine levels, as an index of heightened 
sympathetic nervous activity, predicts mortality in cardiovascular disease, such as chronic 
congestive heart failure [Cohn, et al. 1984; Brum, et al. 2006], left ventricular dysfunction 
[Benedict, et al. 1996] and end-stage renal disease (ESRD) [Masuo, et al. 2007; Ksiazek, et al. 
2008]. Renal injury also predicts the development of cardiovascular disease [Joles, et al. 
2004; Masuo, et al. 2007].  
These investigations have shown strong associations between sympathetic nervous 
activation, cardiovascular complications and renal complications. Given these observations 
it may be of importance to aim antihypertensive treatments or anti-diabetic treatment not 
only at the reduction of raised blood pressure or blood glucose but also at the excessive 
sympathetic activation and insulin resistance that may underpin these effects. 
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5.3. Sympathetic nerve hyperactivity in patients with ESRD 
Evidence now strongly indicates a role for the sympathetic nervous system in the 
pathogenesis of hypertension in renal failure (ESRD) [Hausberg, et al. 2002; Schlaich, et al. 
2009; Masuo, et al. 2010a].  Hypertension occurs commonly and early in renal disease and is 
paralleled by increases in sympathetic nerve activity, as indicated by increased muscle 
sympathetic nerve activity and circulating norepinephrine. This appears to be driven by the 
diseased kidneys, because nephrectomy or denervation has been shown to correct blood 
pressure and sympathetic nerve activity both in human and animal studies [Jacob, et al. 
2003].  
Masuo et al. [Masuo, et al. 1995 & 2010] showed that plasma norepinephrine levels  were 
significantly higher in patients with ESRD regardless of hemodialysis compared with those 
in blood pressure- and body mass index-matched hypertensive patients or healthy 
normotensive subjects (Figure 3). Further, this was recognized significantly in subjects with 
a shorter duration of ESRD with hemodialysis compared with those with longer duration, 
suggesting that sympathetic nerve hyperactivity may be of particular importance in the 
onset or the early development of ESRD or, alternatively, be influenced by long-term renal 
replacement therapy (hemodialysis). In the normal state, interactions between the kidney 
and sympathetic nervous system serve to maintain blood pressure and glomerular filtration 
rate within tightly controlled levels, but in renal failure, a defect in renal sodium excretory 
function leads to an abnormal pressure natriuresis relationship and activation of the renin-
angiotensin system (RAS), contributing to the development of hypertension and progression 
of kidney disease [Hall, et al. 1997; Lohmeier, et al. 2001]. Another mechanism could involve 
the sympathetic nervous modulation of baroreflex regulation and vasculature tone through 
the central nervous system and angiotensin II [Burke, et al. 2008]. Afferent signals from the 
kidney, detected by chemoreceptors and mechanoreceptors, feed directly into central nuclei 
regulating sympathetic nerve activity by circulating and brain-derived angiotensin II 
[Philips, et al. 2005]. Therefore, the pathogenesis of hypertension in renal failure (ESRD) is 
complex and arises most likely from the interaction of hemodynamic and neuroendocrine 
factors. Sympathetic nerve activity has strong relationships with regards to increased risk of 
cardiovascular disease including hypertension [Zoccali, et al. 2002a & 2002b] in patients with 
ESRD and the mortality and morbidity of cardiovascular disease, suggesting that we have to 
pay much attention to sympathetic nerve activation in our attempts to adequately treat 
patients with ESRD. 
Sympathetic nerve activity is consistently elevated in patients with ESRD, and in obese 
subjects and hypertensive patients in cross-sectional studies [Masuo, et al. 1995, 2011a & 
2011b).  The sympathetic nerve hyperactivity is at least in part independent of increased 
blood pressure levels or obesity. Further, patients with early-ESRD without hemodialysis 
had already significantly higher plasma norepinephrine levels compared with hypertensive 
subjects as well as normotensive subjects. Therefore, sympathetic nervous activation in 
ESRD patients may be independent from obesity or hypertension.  
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ESRD, end-stage renal disease; *P<0.05 versus healthy controls; **P<0.01 versus healthy controls;  
#P<0.05 versus hypertensive patients with normal renal function; ##P<0.01 versus hypertensive patients with normal 
renal function. [Masuo, et al. 2010a] 
Figure 3. Figure 3. Comparisons of plasma norepinephrine levels between patients with patients with 
ESRD, hypertensive patients with normal renal function and normal healthy controls.  
The amount of norepinephrine in plasma is only a fraction of the amount released into the 
synaptic cleft, and plasma norepinephrine levels are affected by dialysis therapy, so it is 
difficult to discount that the elevated plasma norepinephrine levels did not derive in part 
from reduced plasma norepinephrine clearance rather than solely from elevated 
sympathetic nerve activity. Grassi et al. [Grassi, et al. 2009] however, reported similar results 
using microneurography. In addition, plasma norepinephrine levels did not change between 
before- and after-hemodialysis therapy (data was not shown), and between after-
hemodialysis therapy and before-next hemodialysis therapy. Thus, one could speculate that 
plasma norepinephrine levels in ESRD patients are reflective of the degree of sympathetic 
nerve activity.   
5.4. β2-adrenoceptor polymorphisms accompanying sympathetic nervous 
activation may relate to renal injury  
Rao et al. [Rao, et al. 2007] and Masuo et al. [Masuo, et al. 2007] have shown strong 
associations between β2-adrenoceptor polymorphisms, elevated plasma norepinephrine 
levels and elevated HOMA-IR (insulin resistance) or future renal injury, suggesting that 
stimulated sympathetic nerve activity associated with insulin resistance, may independently 
play a major role in the onset and development of ESRD without obesity or hypertension. 
However, the precise mechanisms underlying sympathetic activation in CKD and ESRD 
have not been clarified. 
 
Insulin Resistance 176 
Furthermore, Masuo et al. [Masuo, et al. 2011b] measured renal function (creatinine, BUN 
and creatinine clearance), plasma norepinephrine levels and HOMA-IR (insulin 
sensitivity) annually over a 5-year period in nonobese, normotensive men with normal 
renal function. Subjects who had a significant deterioration of renal function (more than 
10% increases from baseline of creatinine and BUN or decrease in creatinine clearance) 
over a 5-year period had higher plasma norepinephrine at the entry period, and greater 
increases in plasma norepinephrine over 5 years [Masuo, et al. 2011b]. In this study, 
subjects who had significant changes in body weight or blood pressure were excluded, 
indicating the contributions of obesity or hypertension might be excluded. Further, 
subjects who had significantly higher levels of plasma norepinephrine had a higher 
frequency of the Gly16 allele of the β2-adrenoceptor polymorphism [Masuo, et al. 2007] 
(Figure 4). The Gly16 allele of the β2-adrenoceptor polymorphism has been shown to be 
related to obesity [Masuo, et al. 2005, 2005a, 2005b], hypertension [Masuo, et al. 2005a, 
2005b, 2010b, 2011c] and metabolic syndrome development [Masuo, et al. 2005b]. Thus, 
high plasma norepinephrine levels appear to be a predictor that is determined genetically 
by the β2-adrenoceptor polymorphism (Arg16Gly) for renal injury, obesity, hypertension 
and metabolic syndrome. 
 
In 154 nonobese, normotensive subjects, renal function (creatinine clearance) was measured over a 5-year period.  
The deterioration of renal function was defined as >10% decreases in creatinine clearance over a 5-year period.  
Subjects with deterioration of renal function had higher frequency of Gly allele or Gly homozygous compared to those 
without changes in renal function. [Masuo, et al. 2011b] 
Figure 4. Subjects with deteriorations of renal function (creatinine clearance) carried higher frequency 
of the Gly16 allele of Arg16Gly, the β2-adrenoceptor polymorphisms  
These observations show that plasma norepinephrine levels associated with insulin 
resistance are strongly linked with the onset and development of renal injury. 
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6. Other medical conditions in obesity  
6.1. Obstructive sleep apnea in obesity is a risk factor for cardiovascular diseases 
Vozoris [Vozoris. 2012] investigated the relationships between prevalence of obstructive 
sleep apnea (OSA), obesity, and hypertension, diabetes, congestive heart failure, myocardial 
infarction, and stroke using a population-based multi-year cross-sectional study design 
including 12,593 individuals with data from the 2005-2008 United States National Health 
and Nutrition Examination Surveys (NHANES). They found individuals with OSA had 
elevated rates of cardiovascular diseases compared to the general population [Vozoris. 
2012]. OSA is a common disorder that has been associated with many cardiovascular disease 
processes, including hypertension and arrhythmias. OSA has also been identified as an 
independent risk factor for stroke and all-cause mortality. OSA is highly prevalent in 
patients with transient ischemic attacks and stroke [Das, et al. 2012]. Indeed, the majority of 
patients with OSA suffer from hypertension [Ziegler, et al. 2011].  The mechanisms 
underlying the link between OSA and cardiovascular disease are not completely 
established. However, there is increasing evidence that autonomic mechanisms are 
implicated. A number of studies have consistently shown that patients with OSA have high 
levels of sympathetic nerve traffic [Narkiewicz, et al. 2003]. In animal studies, intermittent 
hypoxia that simulates changes seen in OSA leads to chemoreceptor and chromaffin cell 
stimulation of sympathetic nerve activity, endothelial damage and impaired blood pressure 
modulation. Human studies reveal activation of sympathetic nerves, endothelial damage 
and exaggerated pressor responses to sympathetic neurotransmitters and endothelin 
[Ziegler, et al. 2011]. OSA is also frequently observed in obese individuals [Dos, et al. 201].2  
6.2. Gout and hyperuricacidemia in obesity 
Gout is a growing worldwide health problem, and is associated with increased prevalence 
of obesity. Gout and hyperuricacidemia are associated with the metabolic syndrome, 
diabetes mellitus, obesity and hypertension. Masuo et al. observed the importance of serum 
uric acid levels as a predictor for future obesity and hypertension [Masuo, et al. 2003]. 
Several epidemiological studies have shown the close linkage between hyperuricemia, 
obesity and hypertension [Robinson, et al. 2012]. Recently Robinson, et al. [Robinson, et al. 
2012] reviewed prevalence of hyperuricemia in Australia in 25 articles and 5 reports using a 
systematic journal search method. From 1968 to 1995/6, the prevalence of gout increased 
from 0.5% to 1.7% of the population. Especially in the Australian indigenous population a 
significant rise in the prevalence of gout from 0% in 1965 to 9.7% in 2002 in males, and 0% to 
2.9% in females were observed. Those elevations were strongly synchronized with the 
prevalence of obesity [Chang, et al. 2001]. Similar result has been reported in Taiwanese 
populations that, using a multivariate analysis, showed that BMI (obesity) was an important 
factor associated with hyperuricemia in both males and females, whereas age was associated 
with hyperuricemia only in males. In addition, the associations of basic and repeated 
measures of uric acid level with treatments for uric acid over a 11-year period, and risk of 
coronary heart disease (CHD) and stroke events were assessed  in Taiwanese populations 
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[Chien, et al. 2005]. The study showed that uric acid had significant risk only in hypertension 
and metabolic syndrome subgroups, but not in their counterparts. They also observed that 
uric acid, in the baseline and time-dependent variables, could predict cardiovascular events 
in the community of relatively low CHD but high stroke risk.  
Straznicky et al. examined the effects of weight loss on serum uric acid levels, and showed 
that it had ameliorative effects on uric acid levels in the obese subjects with the metabolic 
syndrome [Straznicky, et al. 2011]. Furthermore, they compared these effects between a mild 
calorie restricted diet alone, combination with a low calorie diet and exercise and control 
groups.  Interestingly, moderate weight loss in obese patients with metabolic syndrome is 
associated with a reduction in serum uric acid levels, albuminuria and an improvement in 
eGFR which is augmented by exercise co-intervention [Straznicky, et al. 2011]. Improvement 
of insulin resistance and sympathetic activation were synchronized with a reduction in 
serum uric acid levels.   
7. Conclusion 
The role of the sympathetic nervous activity and insulin resistance plays important roles in 
the etiology of obesity, hypertension, and type 2 diabetes. Several investigations have 
demonstrated that the sympathetic nervous activation and insulin resistance are strongly 
related to cardiovascular complication (i.e. LVH, congestive heart failure) and the onset and 
development of ESRD (renal injury).  Interestingly, relevant investigations of sympathetic 
nervous activity and β2-adrenoceptor polymorphisms indicate their contribution to the 
onset and maintenance of renal injury and LVH in healthy subjects and in patients with 
chronic renal failure and cardiovascular events in ESRD patients. Interestingly, the 
prevalence of OSA and hyperuricemia (gout) are significantly linked with increases in 
obesity, and both states are connected with the cardiovascular risks associated with 
sympathetic nervous activation. Serum uric acid, which may be affected strongly by 
sympathetic nervous activity, may be a predictor for future hypertension and renal injury 
(ESRD) development.   
Recently, it has been demonstrated that renal sympathetic nerve denervation provides 
promising results in patients with refractory hypertension [Krum, et al. 2009; Symplicity 
HTN-1 Investigators. 2011]. Besides the demonstrable effect on reducing blood pressure, 
renal denervation significantly and favourably influences LV mass and improves diastolic 
function, which might have important prognostic implications in patients with resistant 
hypertension at high cardiovascular risk [Brandt, et al. 2012]. Further, renal denervations 
showed an accompanying improvements in insulin resistance [Mahfoud, et al. 2011,:  
Witkowski, et al. 2012] and OSA [Brandt, et al. 2011]. Renal sympathetic denervation may 
conceivably be a potentially useful option for patients with co-morbid refractory 
hypertension, glucose intolerance, and obstructive sleep apnea. 
A better understanding of the relationships between sympathetic nervous activity, insulin 
resistance, cardiovascular complications, and renal complications, will help to develop 
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appropriate treatment strategies targeting renal injury or cardiac risk in hypertensive and 
diabetes patients with and without ESRD or LVH.  
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